A Phase 2/3, Multicenter, Open-label Trial to Evaluate the Long-term Safety, Tolerability, and Efficacy of Sibeprenlimab Administered Subcutaneously in Subjects With Immunoglobulin A Nephropathy.
A Phase 2/3, Multicenter, Open-label Trial to Evaluate the Long-term Safety, Tolerability, and Efficacy of Sibeprenlimab Administered Subcutaneously in Subjects With Immunoglobulin A Nephropathy.
To evaluate the long-term safety and tolerability of sibeprenlimab in subjects with IgAN
This is a phase 2/3, multicenter, open-label trial to evaluate the long-term safety, tolerability, and efficacy of sibeprenlimab administered subcutaneously (SC) to subjects with IgAN.
Eligible subjects will have participated in trials 417-201-00007 or VIS649-201 and, in the investigator's judgement, could benefit from continued treatment with sibeprenlimab.
Inclusion Criteria:
Exclusion Criteria:
Saint Leonards, New South Wales 2065, Australia
Greenfield Park, Quebec J4V 2H1, Canada
Sr Priest En Jarez, Pays de la Loire Region 42270, France
Chandigarh, Punjab 160012, India
Rajipet, Tamil Nadu 632517, India
Kfar Saba, 44281, Israel
Petach Tiqwa, 49100, Israel
Genova, 16132, Italy
Toyoake-shi, Aichi-ken 470-1192, Japan
Urayasu-shi, Chiba 279-002, Japan
Kawasaki-shi, Kanagawa 213-8587, Japan
Bunkyo, Tokyo 113-8431, Japan
Nerima-ku, Tokyo 177-8521, Japan
Ellenboro, 28040, Spain